--- title: "outcome after IVIG for cognitive impairment due to Alzheimer | Sutter Health" description: "Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease" url: "https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. outcome after IVIG for cognitive impairment due to Alzheimer # Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease _BMC Neuroscience_ 2099-12-31 ## Abstract Background:The purpose of this study was to assess the five-year treatment effects of a short course of intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) due to Alzheimer disease (AD). Methods:Fifty subjects 50 to 84 years of age with MCI due to AD were administered 0.4 g/kg 10% IVIG or 0.9% saline every two weeks x five doses in a randomized double-blinded design as part of a two-year study. Twenty-seven subjects completed an additional three-year extension study. MRI brain imaging, cognitive testing, and conversion to dementia were assessed annually. Participants were stratified into early MCI (E-MCI) and late MCI (L-MCI). The primary endpoint was brain atrophy measured as annualized percent change in ventricular volume (APCV) annually for five years. ANOVA was used to compare annualized percent change in ventricular volume from baseline between the groups adjusting for MCI status (E-MCI, L-MCI). Results:Differences in brain atrophy between the groups, which were statistically significant after one year, were no longer significant after five years. IVIG-treated L-MCI subjects did demonstrate a delay in conversion to dementia of 21.4 weeks. Conclusion:An eight-week course of IVIG totaling 2 g/kg in MCI is safe but is not sufficient to sustain an initial reduction in brain atrophy or a temporary delay in conversion to dementia at five years. Other dosing strategies of IVIG in the early stages of AD should be investigated to assess more sustainable disease-modifying effects. [PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/34362303/) ![Shawn J Kile, M.D.](https://dyn.mktgcdn.com/p/q0wjBudDBEScUW_Fehb6xrCnhqVyTm2ZGn3nY5fkqXc/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Shawn J Kile, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/shawn-j-kile-md-1049681124) ![Carol Parise, Ph.D.](https://www.sutterhealth.org/static/images/sutter-fallback-image-3-4.jpg) Carol Parise, Ph.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/carol-parise-phd-1049681206) ## Research topics - [Alzheimer's Disease](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Alzheimer%27s+Disease%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia](https://www.sutterhealth.org/research/publications/ivig-treatment-of-mild-cognitive-impairment-1055312456) Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21. J Neurol Neurosurg Psychiatry. 2015 Sep 29. pii: jnnp-2015-311486. doi: 10.1136/jnnp-2015-311486. 2015 Sep 29 - Publication ### [Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment](https://www.sutterhealth.org/research/publications/reduction-amyloid-after-treatment-ivig-for-mild-impairment-1055312939) American Journal of Alzheimer's Disease & Other Dementias 2020 Feb 12 - Publication ### [Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease](https://www.sutterhealth.org/research/publications/alzheimer-abnormalities-of-the-amygdala-1055312743) Arch Neurol. 2009 Jan;66(1):125-9. doi: 10.1001/archneurol.2008.517. Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease. Kile SJ1, Ellis WG, Olichney JM, Farias S, DeCarli C. Author information 1Department of Neurology, University of California at Davis Arch Neurol. 2009 Jan; 2009 Jan 20 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"outcome after IVIG for cognitive impairment due to Alzheimer"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927#medicalscholarlyarticle","name":"Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease","headline":"outcome after IVIG for cognitive impairment due to Alzheimer","abstract":"Background:The purpose of this study was to assess the five-year treatment effects of a short course of intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) due to Alzheimer disease (AD). Methods:Fifty subjects 50 to 84 years of age with MCI due to AD were administered 0.4 g/kg 10% IVIG or 0.9% saline every two weeks x five doses in a randomized double-blinded design as part of a two-year study. Twenty-seven subjects completed an additional three-year extension study. MRI brain imaging, cognitive testing, and conversion to dementia were assessed annually. Participants were stratified into early MCI (E-MCI) and late MCI (L-MCI). The primary endpoint was brain atrophy measured as annualized percent change in ventricular volume (APCV) annually for five years. ANOVA was used to compare annualized percent change in ventricular volume from baseline between the groups adjusting for MCI status (E-MCI, L-MCI). Results:Differences in brain atrophy between the groups, which were statistically significant after one year, were no longer significant after five years. IVIG-treated L-MCI subjects did demonstrate a delay in conversion to dementia of 21.4 weeks. Conclusion:An eight-week course of IVIG totaling 2 g/kg in MCI is safe but is not sufficient to sustain an initial reduction in brain atrophy or a temporary delay in conversion to dementia at five years. Other dosing strategies of IVIG in the early stages of AD should be investigated to assess more sustainable disease-modifying effects.","description":"Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease","keywords":["Alzheimer's Disease"],"datePublished":"2099-12-31","url":"https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"34362303"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/34362303/"],"isPartOf":{"@type":"Periodical","name":"BMC Neuroscience"},"about":[{"@type":"DefinedTerm","name":"Alzheimer's Disease","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Alzheimer%27s+Disease%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/outcome-after-ivig-for-cognitive-impairment-due-to-alzheimer-1055312927#breadcrumblist"}}} ```